(66 days)
The DYNASTY® BIOFOAM® Shells are intended for use in cementless total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients.
Indications for Use
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia;
- inflammatory degenerative joint disease such as rheumatoid arthritis;
- correction of functional deformity; and,
- revision procedures where other treatments or devices have failed.
The DYNASTY® BIOFOAM® Shell is intended for cementless hip arthroplasty.
Design features of the shells are summarized below:
- Shells manufactured from Titanium alloy substrate, coated with BIOFOAM® coating manufactured from commercially pure (CP) titanium
- Solid shell sizes: 46mm-68mm outer diameter
- Three different hole patterns:
- 10-hole shell sizes: 46mm-76mm outer diameter
- 3-hole shell sizes: 46mm-68mm outer diameter
- 5-hole shell sizes: 46mm-50mm outer diameter
The DYNASTY® BIOFOAM® Shells are identical to previously cleared devices, except that the subject device posses different screw hole patterns. Additionally, the DYNASTY® BIOFOAM® Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the DYNASTY® BIOFOAM® Shells are equivalent to predicate devices.
The provided text is related to a 510(k) summary for a medical device called the DYNASTY® BIOFOAM® Shell, an acetabular cup for hip arthroplasty. The document describes the device, its intended use, and its substantial equivalence to predicate devices. However, it does not describe any clinical study or testing with acceptance criteria and reported device performance in the way a typical AI/ML device submission would.
The core of this submission is based on substantial equivalence to previously cleared devices (DYNASTY® Acetabular System K082924). The key statement that replaces a detailed performance study is:
"The DYNASTY® BIOFOAM® Shells are identical to previously cleared devices, except that the subject device posses different screw hole patterns. Additionally, the DYNASTY® BIOFOAM® Shells were evaluated via post-impaction analysis of clearance, form and frictional torque. A review of these results indicates that the DYNASTY® BIOFOAM® Shells are equivalent to predicate devices."
And:
"The safety and effectiveness of the DYNASTY® BIOFOAM® Shells are adequately supported by the substantial equivalence information, materials information, and analysis data provided within this Premarket Notification."
Therefore, I cannot provide the requested information about acceptance criteria or a study proving the device meets them because such a study, with the specific details requested, is not present in this 510(k) summary. The submission relies on demonstrating equivalence through design and limited engineering analysis (post-impaction analysis).
Here's a breakdown of why this information is missing based on the document:
- No new clinical study: The document explicitly states the device is "identical to previously cleared devices, except that the subject device posses different screw hole patterns." This indicates that a comprehensive, new clinical performance study, often required for novel devices or significant changes, was not performed or deemed necessary.
- Reliance on Predicate Device Performance: The safety and effectiveness are established by the substantial equivalence to the predicate device (DYNASTY® Acetabular System, K082924). The performance of the predicate device is implicitly accepted.
- Limited "Evaluation" mentioned: The only "evaluation" mentioned is "post-impaction analysis of clearance, form and frictional torque." This is an engineering/benchtop test, not a clinical study involving patients or expert review. The document does not provide specific acceptance criteria or results for this analysis beyond stating it indicates equivalence.
In summary, the provided text does not contain the information required to answer your specific questions regarding acceptance criteria and a study proving their fulfillment, as it describes a 510(k) submission based on substantial equivalence and engineering analysis rather than a clinical performance study.
§ 888.3330 Hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis.
(a)
Identification. A hip joint metal/metal semi-constrained, with an uncemented acetabular component, prosthesis is a two-part device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that consist of a femoral and an acetabular component, both made of alloys, such as cobalt-chromium-molybdenum. The femoral component is intended to be fixed with bone cement. The acetabular component is intended for use without bone cement (§ 888.3027).(b)
Classification. Class III.(c)
Date PMA or notice of completion of PDP is required. A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before May 18, 2016, for any hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976, or that has, on or before May 18, 2016, been found to be substantially equivalent to a hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component that was in commercial distribution before May 28, 1976. Any other hip joint metal/metal semi-constrained prosthesis with an uncemented acetabular component shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.